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Rapport de synthèse 
Plusieurs investigateurs ont démontré que l'utilisation d'une antibiothérapie 
prophylactique lors d'interventions neurochirurgicales en terrain non infecté (chirurgie 
propre) réduisait le taux d'infection. Toutefois, ces taux d'infections sont très 
variables en fonction des types de chirurgie et de la durée des interventions. Les 
craniotomies, la mise en place ou le remplacement de shunt ventriculo-cardiaque, 
l'extirpation de méningiomes intracrâniens et les interventions d'une durée de plus de 
quatre heures sont grevées d'un taux d'infections post-opératoires plus élevé. Si une 
prophylaxie antibiotique est maintenant reconnue et utilisée dans ce type de 
chirurgie, il n'a jamais été démontré que cette pratique amène un bénéfice dans les 
cas de chirurgie pour hernie discale. Des études ont montré que de nombreux 
organismes potentiellement pathogènes pouvaient être collectés et cultivés à 
proximité voire dans le champ opératoire. Malgré ces observations, le taux 
d'infections post-opératoires reste peu important (entre 1-4% selon les centres). Il 
n'est actuellement pas possible de distinguer le rôle respectif d'une antibiothérapie 
prophylactique et des pratiques d'asepsie habituelles (y compris l'usage de solutions 
de rinçage antiseptiques) dans la faible incidence des infections post-opératoires en 
ce qui concerne la chirurgie des hernies discales. Lorsque des opérations de 
chirurgie dite « propre » sont grevées d'un taux de complications aussi bas, une 
prophylaxie antibiotique n'est généralement pas recommandée, en raison d'un 
rapport coût-bénéfice défavorable. 
Le but de cette étude est d'évaluer la nécessité d'une antibiothérapie prophylactique 
par une céphalosporine de seconde génération (cefuroxime 1,5 g intraveineuse) 
dans la prévention des infections post-opératoires au cours d'une chirurgie pour 
hernie discale. Il s'agit d'un essai clinique prospectif, contrôlé contre placebo en insu 
réciproque, à répartition aléatoire. 
L'étude a été conduite dans les services de neurochirurgie de !'Hôpital Universitaire 
de Genève et du Centre Hospitalier Universitaire Vaudois de Lausanne. L'ensemble 
des patients admis dans ces deux services pour une opération de hernie discale et 
ayant donné leur consentement ont été inclus dans l'étude qui s'est déroulé sur une 
période de 6 ans. 
Mille trois cent soixante-neuf patients opérés pour une hernie discale ont été inclus 
dans cet essai et 132 patients ont été exclus de l'analyse pour diverses raisons. Au 
total 1 '237 patients ont été analysés, respectivement 613 et 624 patients dans le 
groupe cefuroxime et le groupe placebo. Les patients des deux groupes présentaient 
des caractéristiques identiques. Nous n'avons objectivé aucun effet secondaire 
indésirable attribuable à la cefuroxime ou au placebo. Huit (1.3%) patients du groupe 
cefuroxime et 18 patients (2.8%) du groupe placebo ont développé une infection du 
site opératoire (P=0.073). Neuf des patients infectés dans le groupe placebo 
présentaient une infection profonde du site opératoire (spondylodiscite, abcès 
épidural) et aucun dans le groupe cefuroxime (P<0.01 ). Tous les patients avec 
infection profonde du site opératoire ont été traités par antibiothérapie par voie 
intraveineuse pour au moins 4 semaines et il a été procédé à une reprise chirurgicale 
chez deux patients. 
Ces résultats montrent qu'il faut traiter 69 patients avec une antibiothérapie 
prophylactique de cefuroxime pour prévenir une infection du site opératoire. 
En conclusion, l'administration d'une dose de cefuroxime 1.5 g intraveineuse comme 
prophylaxie lors d'opération de hernie discale, permet de réduire significativement le 
risque d'infection profonde du site opératoire. 
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Cefuroxime Prophylaxis Is Effective in 
N oninstrumented Spine Surgery 
A Double-Blind, Placebo-Controlled Study 
Christiane Petignat, MD,* Patrick Francioli, MD,* Stephan Harbarth, MD, MS,t 
Luca Regli, MDJ François Porchet, MDJ Alain Reverdin, MD,§ Benedict Rilliet, MD,§ 
Nicolas de Tribolet, MD,§ André Pannatier, PharmD,~ Didier Pittet, MD, PhD,t 
and Giorgio Zanetti, MD, MS* 
Study Design. Double-blind, placebo-controlled ran-
domized clinical trial. 
Objective. To assess the efficacy of 1 preoperative 
1.5 g dose of cefuroxime in preventing surgical site infec-
tion after surgery for herniated dise. 
Summary of Background Data. Antibiotic prophylaxis 
was only tested in nonconclusive trials in this setting. 
Methods. The study was conducted in 2 university 
hospitals in Switzerland. Patients were assessed for oc-
currence of surgical site infection {defined by the criteria 
of the Centers for Diseases Control and PreventionL other 
infections, or adverse events up to 6 months after sur-
gery. Outcome measures were compared in a univariate, 
per-protocol analysis. 
Results. Baseline characteristics were similar in pa-
tients allocated to cefuroxime {n = 613) or placebo {n = 
624). Eight (1.3%) patients in the cefuroxime group and 18 
patients (2.8%) in the placebo group developed a surgical 
site infection {P = 0.073). A diagnosis of spondylodiscitis 
or epidural abscess was made in 9 patients in the placebo 
group, but none in the cefuroxime group (P < 0.01 L which 
corresponded to a number necessary to treat of 69 pa-
tients to prevent one of these infections. There were no 
significant adverse events attributed to either cefuroxime 
or placebo. 
Conclusion. A single, preoperative dose of cefuroxime 
significantly reduces the risk of organ-space infection, most 
notably spondylodiscitis, after surgery for herniated dise. 
Key words: antibiotic prophylaxis, bacterial infections/ 
prevention and control, surgical wound infection/prevention 
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Several clinical trials have shown that antibiotic prophy-
laxis is effective in reducing surgical site infections after 
neurosurgical procedures, such as craniotomies, 1 shunt 
replacement procedures,2'3 extirpation of cerebral me-
ningiomas, and operations lasting for more than 4 
hours.4'5 Antibiotic prophylaxis is now generally recom-
mended for these procedures.6 - 9 Many surgeons also ad-
minister prophylactic antibiotics in spinal surgery, al-
though the benefit of this practice has never been 
demonstrated in a double-blind randomized trial. Others 
argue that antibiotic use may unnecessarily expose pa-
tients to adverse drug reactions, encourage the emer-
gence of resistant bacteria, and increase costs. This opin-
ion is based on the fact that clean surgical procedures like 
spinal surgery carry a low risk of infection, which implies 
that the expected number of patients who should receive 
prophylaxis to avoid one infection would necessarily be 
high. 
A recent meta-analysis of 6 open, prospective, non-
randomized trials or subgroup analyses1 enrolling 843 
patients suggested that prophylactic antibiotics were 
beneficial for spinal surgery, even if infection rates in the 
absence of antimicrobial prophylaxis were as low as 
5.9%. The odds ratio was 0.37 (95% confidence inter-
val, 0.17-0.78) favoring antibiotic prophylaxis. How-
ever, meta-analyses are not exempt from bias. In a num-
ber of areas of clinical controversy in which 
nonrandomized trials were unable to yield a clinical con-
sensus, randomized clinical trials produced clear results 
while exposing far fewer patients to ineffective thera-
py.2'10 Moreover, the above-mentioned meta-analysis 
did not distinguish superficial and deep surgical site in-
fections, particularly spondylodiscitis, the burden of 
which is substantially different. 
The purpose of the present double-blind, randomized 
trial was to assess the efficacy of antibiotic prophylaxis in 
preventing infections after spinal surgery. Cefuroxime 
was chosen since current guidelines commonly recom-
mend first- or second-generation cephalosporins when 
prophylaxis is indicated for clean surgery.u 
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• Materials and Methods 
Patients and Setting 
This randomized, placebo-controlled, double-blind trial was 
performed in one neurosurgery department that included 2 ser-
vices, 1 at the Centre Hospitalier Universitaire Vaudois, Lau-
sanne, and the other at the University of Geneva Hospitals, 
Geneva (Switzerland). The study protocol was approved by the 
ethical review committees of the 2 institutions. 
Patients older than 18 years requiring spinal surgery for 
herniated dise (hemilaminectomy, laminectomy, flavectomy, 
spondylosyndesis) were recruited from April 1994 through 
March 2000. Exclusion criteria were: known or suspected hy-
persensitivity to cephalosporins or type I hypersensitivity to 
betalactams; severe renal fonction impairment; acquired im-
mune deficiency syndrome or other conditions of severe im-
muno-suppression; antibiotic therapy for concomitant infec-
tion at the time of surgery; refusa! to participa te; or pregnancy. 
Study Design and Intervention 
Once informed consent was obtained, eligible patients were 
allocated to receive one numbered via! of either 1.5 g of intra-
venous cefuroxime (Zinacef, GlaxoSmithKline AG München-
buchsee, Switzerland) or a placebo of identical appearance. 
Randomization was performed by the hospital pharmacist ac-
cording to a computer-generated random scheme. The alloca-
tion was blinded to the surgeon, the patient, and the study 
investigator. Both placebo and cefuroxime were prepared and 
numbered by the hospital pharmacies, and were administered 
intravenously by the anesthesiologist at the time of induction. 
The timing of administration was not supervised but was doc-
umented on the anesthesiology sheet. The surgeon was asked 
about the occurrence of a break in asepsis during operation. 
Patients were observed prospectively during hospitaliza-
tion by a study nurse (and an investigator in case of any 
abnormal findings), and the following information was re-
corded: temperature, symptoms or signs of infection, diag-
nostic tests performed, and prescription of antibiotics, anal-
gesics or anti-inflammatory drugs. Ail patients were seen by 
the surgeon-in-charge 6 weeks after the operation. During 
this follow-up visit, a standardized questionnaire recorded 
information about difficulties in wound healing, evidence of 
any infection during follow-up, unscheduled visits to a phy-
sician and prescription of antibiotics. 12 Al! patients were 
also seen or contacted by phone at 3 and 6 months after the 
operation to collect standardized follow-up data. 
Outcome Measures 
Surgical site infection was the primary outcome, defined ac-
cording to the criteria of the Centers for Disease Control and 
Prevention.13 In brief, a superficial infection of the incision site 
was diagnosed in the presence of clinical signs of infection that 
involved the skin, subcutaneous tissue, or muscle located above 
the fascia! layer and accompanied by at least one of the follow-
ing criteria: purulent drainage located above the fascia! layer 
and/or isolation of a microorganism from a wound culture 
showing signs of inflammation. A deep incisional infection was 
diagnosed when infection was found to in volve tissue below the 
fascia on opening and exploration by the surgeon. An organ-
space infection was diagnosed when clinical and imaging (CT-
scan or magnetic resonance imaging) signs were suggestive of 
an infection of a dise, a vertebra, or a paravertebral structure, 
associated or not with a positive culture of blood or of material 
obtained by needle aspiration of the vertebral space, needle 
biopsy of the bone, or open bone biopsy. Postoperative infec-
tions other than surgical site infections were diagnosed accord-
ing to CDC criteria, 8 which included a diagnosis of infection by 
the surgeon. 
Al! included patients were monitored for signs of drug tox-
icity and serious adverse events, such as Clostridium di(ficile-
associated colitis, allergie reaction or anaphylactic shock. 
Statistical Analysis 
We evaluated clinical outcomes in a per-protocol analysis that 
included ail randomized patients who had received the study 
drug and completed follow-up at 6 weeks. Patients who did not 
complete the protocol until the follow-up visit at 6 weeks were 
excluded from this analysis. 
Assuming an infection rate of 3% in the placebo group and 
O. 75% in the antibiotic group, 1' 11 656 patients per group were 
required to detect the difference with a power of 0.8 at a sig-
nificance level of 0. 05 (2-sided tests). Baseline characteristics 
and outcomes were compared in univariate analyses, using X2 
test (or Fisher exact test when appropriate) for categorical vari-
ables and the Wilcoxon rank sum test for continuous variables. 
The code of the study was broken after ail analyses had been 
performed. 
Role of the Funding Source 
The study sponsor had no role in designing the study, the man-
agement and the analysis of data, the writing and the submis-
sion of this article. 
Ill Results 
Of the 1369 patients who initially fulfilled inclusion cri-
teria, 132 (9.6%) were excluded from the analysis for the 
following reasons: 107 patients (59 in the cefuroxime 
group and 48 in the placebo group) because they did not 
receive the study medication; 5 patients (2 in the cefu-
roxime group and 3 in the placebo group) because of lack 
of follow-up at 6 weeks; and 20 patients for other rea-
sons ( 11 in the cefuroxime group and 9 in the placebo 
group). (Figure 1). Among the 1237 patients analyzed, 
613 received cefuroxime and 624 received the placebo. 
Follow-up was possible in 1232 patients at 3 months and 
in 1222 at 6 months. Patients in both groups were similar 
with respect to baseline characteristics (Table 1). 
Infections 
A total of 71 infections were recorded in 70 patients, of 
which 30 occurred during hospitalization. The overall 
rate of infection was 5.2% (32/613) in the cefuroxime 
group and 6.3% (39/624) in the placebo group (P 
0.44). 
Surgical Site Infections 
Eight patients who received cefuroxime (8/613, 1.30%) 
and 18 patients who received placebo (18/624, 2.9%) 
developed a surgical site infection (relative risk with ce-
furoxime: 0.45, 95% confidence interval 0.20-1.03, P = 
0.07), which corresponded to a number necessary to 
treat of 63 patients to avoid one surgical site infection. 
The characteristics of the patients with surgical site in-
fections are detailed in Tables 2 and 3. 
There were 6 incisional wound infections in the cefu-
roxime group and 7 in the placebo group, and 2 deep 
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1 
1 ,369 patients randomised 1 
~~ 
Allocated to cefuroxime (n=685) Allocated to placebo (n=684) 
Figure 1. Randomization, follow-
up, and data analysis for study 
participants. 
- 626 received allocated 
intervention 
- 59 did not receive allocated 
intervention 
Ir 
Lost to follow-up al 6 weeks 
(n=2) 
Ir 
Analyzed (n = 613) 
(excluded from analysis : 11) 
wound infections in each group. Nine patients in the 
placebo group presented an organ-space infection (doc-
umented microbiologically in ail but one), most notably 
spondylodiscitis, compared to none in the cefuroxime 
Table 1. Baseline Characteristics of the Patients in the 
TINo Study Groups* 
Male(%) 
Median age in years (range) 
Elective operation (%) 
Laminectomy (%) 
Hemilaminectomy (%) 
Discectomy (%) 
Combined operation (%) 
Bane graft (%) 
Surgery on one intervertebral space (%) 
Lumbar operation (%) 
Broken asepsis during operation 
Comorbidities (%) 
Median length of operation in minutes (range) 
Cefuroxime Placebo 
n = 613 n = 624 
380 (62) 
46 (18-86) 
596 (97) 
110 (18) 
252 (41) 
242 (39) 
9 (1) 
10 (2) 
531 (87) 
542 (88) 
10 (1) 
19 (3) 
77 (23-270) 
382 (61) 
45 (19-85) 
606 (97) 
87 (14) 
261 (42) 
267 (43) 
9 (1) 
15 (2) 
563 (90) 
539 (86) 
10 (1) 
13 (2) 
73 (15-355) 
*There was no significant difference between the groups. 
- 636 received allocated 
( Allocation ) intervention 
- 48 did not receive allocated 
intervention 
Lost to follow-up al 6 weeks [ Follow-Up J (n=3) 
Analyzed (n= 624) [ Analysis J (excluded from analysis: 9) 
group (P < 0.01), which corresponded to a number neces-
sary to treat of 69 patients to avoid one infection. Ali these 
patients were treated with systemic antibiotics for 4 weeks 
or more, and 5 of 9 required reintervention (Table 3). 
Five of the 18 surgical site infections in the placebo 
group (2 spondylodiscitis and 3 wound infections), but 
none of the 8 infections in the cefuroxime group were 
diagnosed during hospital stay. The microorganisms re-
covered from wound infections were Staphylococcus au-
reus, S. epidermidis, S. lugdunensis, Klebsiella pneu-
moniae, and Propionibaterium acnes. Ali were susceptible 
to second-generation cephalosporins (even the S. epidermi-
dis strains). 
Other Infections 
Sixteen nonsurgical site infections occurred in each of the 
study group. Nine of the 16 urinary tract infections were 
documented microbiologically: 4 in the placebo group 
(ail caused by Escherichia coli susceptible to cefuroxime) 
and 5 in the cefuroxime group (caused by K. pneu-
moniae, Morganella morganii, Citrobacter braakii, En-
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Table 2. Characteristics of lncisional and Deep Wound Infections 
Type of CDC Criteria for Local Systemic lnterval Since 
Case Number Surgery Diagnosis Microbiology Treatment Antibiotics Operation (d) 
lncisional wound infections 
Cefuroxime group 
1 H Physician's diagnosis* Not obtained Local care Yes 12 
2 H Physician's diagnosis* Not obtained Local care No 5 
3 H Physician's diagnosis* Not obtained Local care Yes 9 
4 D Physician's diagnosis* Not obtained Local care No 5 
5 D Purulent discharge Not obtained Local care No 28 
6 H Abscess Negative Incision and Yes 9 
slitting up 
Placebo group 
7 H Physician's diagnosis* Not obtained Slitting up No 16 
8 H Physician's diagnosis* Staphylococcus epidermidis Slitting up Yes 6 
9 L Physician's diagnosis* Not obtained No Yes 18 
10 D Physician's diagnosis* Not obtained No No 30 
11 H Purulent discharge Not obtained No No 19 
12 H Abscess Not obtained Incision and No 15 
slitting up 
13 H Purulent discharge Not obtained Slitting up No 9 
Deep wound infection 
Cefuroxime group 
14 D Purulent discharge Not obtained No Yes 9 
15 D Scar dehiscence, Staphylococcus aureus Slitting up Yes 17 
inflammation and 
discharge 
Placebo group 
16 L Scar dehiscence, Staphy/ococcus aureus Slitting up Yes 6 
inflammation and 
discharge 
17 c Scar dehiscence, Klebsiella pneumoniae Slitting up Yes 18 
inflammation and 
discharge 
* According to predefined criteria. 
CDC indicates Centers for Disease Contrai and Prevention, Atlanta (Ge); L, laminectomy; H, hemilaminectomy; D, discectomy; C, combined operation. 
terococcus spp, E. coli, and Pseudomonas aeruginosa, all 
resistant to second generation cephalosporins). 
Side Effects 
There was no significant sicle effect attributable to either 
cefuroxime or placebo. 
11111 Discussion 
The present double-blind, placebo-controlled study 
showed the substantial effect of one single dose of prophy-
lactic cefuroxime in preventing the most severe surgical site 
infections in patients undergoing spinal surgery. 
Table 3. Characteristics of Space Infections and Spondylodiscitis (Ali in the Placebo Group) 
Microbiology 
Case Type of lnterval Since 
Number Surgery Description Surgical Treatment Local Specimen* Blood Operation (d) 
H Discitis and muscular abscess Slitting up Staphylococcus Sterile 28 
epidermidis 
2 D Discitis, cervical and mediastinal Slitting up, vertebral Staphy/ococcus Propionibacterium acnes 16 
abscesses repair epidermidis, 
Propionibacterium 
acnes 
3 H Epidural abscess Slitting up Staphylococcus Staphylococcus aureus 4 
aureus 
4 H Discitis and paravertebral Slitting up Sterile Sterile 35 
abscesses 
5 H Discitis None Staphylococcus Sterile 174 
epidermidis 
6 D Epidural abscess Slitting up Staphylococcus Sterile 17 
epidermidis 
7 D Spondylodiscitis None Not done Propionibacterium acnes 86 
8 D Spondylodiscitis None Not done Staphy/ococcus 60 
/ugdunensis 
9 D Spondylodiscitis None Propionibacterium Sterile 72 
acnes 
*Surgical specimen or CT-scan guided needle aspiration. 
H indicates hemilaminectomy; D, discectomy. 
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To our knowledge, this study is the first to clearly 
demonstrate such an effect in this setting that carries a 
low risk of infection. Recently, a meta-analysis of 6 se-
lected, open, randomized trials or trial subgroups also 
concluded that antibiotic prophylaxis was beneficial for 
spinal surgery.1 The rate of surgical site infection was 
5.9% in this meta-analysis for patients without antibiot-
ics. Of particular interest is the fact that this rate was 2 
times lower in the control group of the present study 
(2.9% ). For such a low level of risk, some experts advise 
against antibiotic prophylaxis for most spinal procedures 
because of possible drug reactions, emergence of antibiotic 
resistant bacteria, and additional costs.14- 18 Others argue 
that prophylaxis should only be used for selected interven-
tions such as interna! fixation or fusion of the spine, as these 
procedures are associated with a higher risk of infection 
than simple discectomies.15'19 In contrast, the present study 
showed a significant prevention of the most severe of these 
infections, i.e., spondylodiscitis and other organ-space in-
fections (0/613 vs. 9/624). 
The reason why the prophylactic effect was only ob-
served against deep-seated wound infections remains un-
clear. An observer bias is unlikely given the double-blind 
design of the study. This finding may reflect the fact that 
in an era where high standards of asepsis are enforced 
during surgical interventions, some of the superficial in-
fections are acquired after surgery. Different from deep 
infections, these late-onset infections could not be pre-
vented through antibiotic prophylaxis. Similarly, there 
was no difference in rates of infections other than surgi-
cal site infections in the present study. However, data are 
scarce in the literature regarding postoperative determi-
nants of surgical site infections.20 
Classic microorganisms were recovered from wound 
infections. 5,l 7,21 ,22 All of them were susceptible to sec-
ond-generation cephalosporins including the S. epider-
midis strains. The external validity of the study may be 
limited for settings with increased resistance of S. epider-
midis to {3-lactam antibiotics, or hyper-endemic occur-
rence of methicillin-resistant S. aureus. 
There was no adverse event reported in relation with 
use of prophylaxis. However, among the microbiologi-
cally-documented urinary tract infections, there was a 
clear shift towards causative microorganisms resistant to 
second-generation cephalosporins in patients who had 
received cefuroxime. Thus, there may be some associa-
tion between cefuroxime use and urinary tract infection 
caused by resistant microorganisms. 17'23 This under-
scores the possible risk related to prolonged use of 
prophylaxis. 24 
The study suffers from several limitations. No infor-
mation was available on the number of patients assessed 
for eligibility. In addition, we did not perform an intent-
to-treat analysis because few patients crossed-over to the 
other assignment arm. Thus, the difference between an 
intent-to-treat analysis and the per-protocol analysis is 
only minimal and would not change the main results. 
Another limitation cornes from the fact that the diagno-
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sis of surgical site infection largely relied on the physician 
in charge. However, the impact of these possible bias or 
confounders is probably very limited thanks to the dou-
ble-blind design of the study. Finally, the present study 
does not prove that cefuroxime was better than other 
antibiotics frequently used for prophylaxis such as first-
generation cephalosporins. 
This double-blind randomized trial demonstrates that 
the administration of a single dose of prophylactic cefu-
roxime before spinal surgery reduces the risk of organ-
space infection and presumably saves costs, although it 
had no impact on other types of surgical site infection or 
on infections at other body sites. Based on these results, a 
formal recommendation for using such a prophylaxis 
should be considered in this setting. 
1111 Key Points 
• This double-blind, placebo-controlled trial dem-
onstrates that the administration of a single dose of 
prophylactic cefuroxime before spinal surgery re-
duces the risk of organ-space infection. 
• According to the results, the prophylactic antibi-
otic should be given to 69 patients to prevent one of 
these infections. 
• To our knowledge, this study is the first to clearly 
demonstrate such an effect in this setting that car-
ries a low risk of infection. 
Acknow/edgments 
We are grateful to N. Weissbrodt, V. Sauvan, C. 
Akakpo, J. Galeazzi, P. Berrault, I. Nahimana, and M. 
Mottaz for their contribution to the study. 
References 
1. Barker FG IL Efficacy of prophylactic antibiotic therapy in spinal surgery: a 
meta-analysis. Neurosurgery 2002;51:391-401. 
2. Haines SJ, Walters BC. Antibiotic prophylaxis for cerebral spinal fluid 
shunts: a meta-analysis. Nettrosurgery 1994;34:87-93. 
3. Langley JM, LeBlanc JC, Drake J, et al. Efficacy of antimicrobial prophylaxis 
in placement of cerebrospinal fluid shunts: meta-analysis. Clin Infect Dis 
1993;17:98-103. 
4. Djindjian M, Lepresle E, Homs JB. Antibiotic prophylaxis during prolonged 
clean neurosurgery. Results of a randomized double-blind study using Ox-
acillin. J Neurosurg 1990;73:383-6. 
5. Tronnier V, Schneider R, Kunz U, et al. Postoperative spondylodiscitis: re-
sults of a prospective study about the aetiology of spondylodiscitis after 
operation for lumbar disk herniation. Acta Neurochir 1992;117:149-52. 
6. Blomstedt GC, Kytta J. Results of a randomized trial of Vancomycin pro-
phylaxis in craniotomy. J Neurosurg 1988;69:216-20. 
7. Geraghty J, Feely M. Antibiotic prophylaxis in neurosurgery. A randomized 
clinical trial. J Neurosurg 1984;60:724-8. 
8. Van Ek B, Dijkmans BAC, Van Dulken H, et al. Antibiotic prophylaxis in 
craniotomy: a prospective double-blind placebo-controlled study. Scand 
J Infect Dis 1988;20:633-9. 
9. Young RF, Lawner PM. Perioperative antibiotic prophylaxis for the preven-
tion of postoperative neurosurgical infections: a randomized clinical trial. 
J Neurosurg 1987;66:701-5. 
10. Altman DG. Systematic reviews of evaluations of prognostic variables. In: 
Egger M, Davey Smith G, Altman D, eds. Systematic Reviews in Health Gare: 
Meta-Analysis in Context. 2nd ed. London: BMJ Books; 2001:228-47. 
11. ASHP Therapeutic Guidelines on antimicrobial prophylaxis in surgery: 
American Society of Health-System Phannacists. Am J Health Syst Pharm 
1999;56:1839-88. 
~opyright CÇ) Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. 
1924 Spine •Volume 33 • Number 18 • 2008 
12. Platt R, Zaleznik DF, Hopkins CC, et al. Perioperative antibiotic prophy-
laxis for herniorrhaphy and breast surgery. N Engl J Med 1990;322: 
153-60. 
13. Garner JS, Jarvis WR, Emori TG, et al. CDC definitions for nosocomial 
infections. Am J Infect Control 1988;16:128-40. 
14. Dauch W A. Infection of the intervertebral space following conventional and 
microsurgical operation on the herniated lumbar intervertebral disk. Acta 
Neurochir 1986;82:43-9. 
15. Dimick JB, Lipset PA, Kostuik JP. Spine update: antimicrobial prophy-
laxis in spine surgery: basic principles and recent advances. Spine 2000; 
25:2544-8. 
16. ] on es ] . Prophylactic use in clean neurosurgery: of potential bene fit or harm 
to the patient. J Wound Gare 2005;14:39-41. 
17. Kernodle DS, Classen DC, Burke JP, et al. Failure of cephalosporins to prevent 
Staphylococcus aureus surgical wound infection.JAMA 1990;263:961-6. 
18. Slama TG, Sklar SJ, Misinski ], et al. Randomized comparison of Cefaman-
dole, Cefazolin and Cefuroxime prophylaxis in open-heart surgery. Antimi-
crob Agents Chemother 1986;29:744-7. 
19. Tenney JH, Vlahov D, Salcman M, et al. Wide variation in risk of wound 
infection following clean neurosurgery. J Neurosurg 1985;62:243-7. 
20. Manian FA, Meyer PL, Setzer ], et al. Surgical site infections associated with 
methicillin-resistant Staphy/ococcus auretts: do postoperative factors play a 
role? Clin Infect Dis 2003;36:863-8. 
21. Savitz SI, Lee LV, Goldstein HB, et al. Investigation of bacteriological factor 
in cervical disk surgery. Mt Sinaï] Med 1994;61:272-5. 
22. Wimmer C, Gluch H, Franzreb M. Predisposing factor for infection in spine 
surgery: a survey of 850 spinal procedures. J Spinal Disord 1998;11:124-8. 
23. Rubinstein E, Findler G, Amit P, et al. Perioperative prophylactic cephazolin 
in spinal surgery. J Bane Joint Surg 1994;76B:99-102. 
24. Harbarth S, Samore MH, Lichtenberg D, et al. Prolonged antibiotic prophy-
laxis after cardiovascular surgery and its effect on surgical site infections and 
antimicrobial resistance. Circulation 2000;101:2916-21. 
~opyri~ht © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. 
